Are your eligible patients using the EPIPEN® Savings Card?

Commercially-insured, eligible patients may save up to $300 on each EPIPEN 2-PAK® and/or EPIPEN JR 2-PAK® carton with the EPIPEN Savings Card. Tell your patients about it and help them reduce their out-of-pocket costs and be prepared in more places. Restrictions apply; see full Terms and Conditions.*

Are your eligible patients who are prescribed the authorized generic to EPIPEN using the Epinephrine Injection, USP Auto-Injector Savings Card?

Commercially-insured, eligible patients may save up to $25 on each Epinephrine Injection, USP Auto-Injector two-pack carton with the Epinephrine Injection, USP Auto-Injector Savings Card. Tell your patients about it and help them reduce their out-of-pocket costs and be prepared in more places. Restrictions apply; see the offer details for full Terms and Conditions.*

*These savings offers are not valid for patients covered by Medicare, Medicaid or any other federal- or state-funded healthcare program or where prohibited by law. Mylan Specialty L.P., a Viatris Company, reserves the right to amend or end these programs at any time without notice.

What if a patient doesn’t have their savings card with them at the pharmacy?

The static ID codes below provide unrestricted access to EPIPEN and its authorized generic and can streamline your workflow.

Static ID Codes
BIN: 610524
RxPCN: Loyalty
Issuer: (80840)
Group: 50777486
ID: 1230782978
  • No more searching for a card, calling to activate or having to apply a number to the claim.
  • Manually input the same static ID for commercially eligible and uninsured patients.
  • When there is a prior authorization (PA), NDC block or step edit, run the script and static ID and send the PA to the office. Once you receive approval, rerun the static ID.

How many EPIPEN 2-PAK (or its authorized generic) cartons does a patient need?

You may notice that doctors are prescribing EPIPEN 2-PAK (or its authorized generic) cartons for multiple locations to help patients be prepared for anaphylactic emergencies. Here’s why it’s important to dispense the appropriate product:

  • Nearly half of anaphylactic reactions occur outside the home—in places like work, school, restaurants, outdoors or while travelling.1
  • Patients should have immediate access to 2 epinephrine auto-injectors at all times, according to the National Institute of Allergy and Infectious Disease (NIAID) guidelines. Up to 20% of patients may require a second dose of epinephrine, due to protracted symptoms or a biphasic reaction. Dispensing multiple cartons helps patients have access to a second dose of epinephrine if they need it.2,3

Ordering information

Here's how to order the EPIPEN Auto-Injector or its authorized generic.4,5

Viatris Auto-Injector NDC number
EPIPEN 2-PAK (0.3 mg) 49502-500-02
EPIPEN JR 2-PAK (0.15 mg) 49502-501-02
Epinephrine Injection, USP (0.3 mg) 49502-102-02
Epinephrine Injection, USP (0.15 mg) 49502-101-02

You can order EPIPEN Auto-Injector or its authorized generic from your wholesaler. For further information, please call 800-796-9526.

Special Offers

Access and Savings Programs link

Viatris offers Access and Savings Programs for eligible patients. See Terms and Conditions.

Learn more here »
Anaphylaxis management page link

There’s only one recommended first-line treatment for anaphylaxis.

Epinephrine, not antihistamines »

Important Safety Information (the following information applies to both EPIPEN and its Authorized Generic)

EPIPEN (epinephrine injection, USP) 0.3 mg and EPIPEN JR (epinephrine injection, USP) 0.15 mg Auto-Injectors are intended for immediate administration as emergency supportive therapy only and are not intended as a substitute for immediate medical or hospital care. In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care. More than two sequential doses of epinephrine should only be administered under direct medical supervision.

EPIPEN and EPIPEN JR should only be injected into the anterolateral aspect of the thigh. Do not inject intravenously, into buttock, or into digits, hands, or feet. Instruct caregivers to hold the leg of young children firmly in place and limit movement prior to and during injection to minimize risk of injection-related injury.

Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop symptoms of infection such as persistent redness, warmth, swelling, or tenderness at the injection site.

Epinephrine should be used with caution in patients with heart disease, and in patients who are on drugs that may sensitize the heart to arrhythmias, because it may precipitate or aggravate angina pectoris and produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics.

Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Common adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties.

Indications (the following information applies to both EPIPEN and its Authorized Generic)

EPIPEN and EPIPEN JR Auto-Injectors are indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. EPIPEN and EPIPEN JR Auto-Injectors are intended for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions.

Click here for Full Prescribing Information for EPIPEN.
Click here for Full Prescribing Information for the Authorized Generic for EPIPEN.

heading

MORE LESS

Important Safety Information (the following information applies to both EPIPEN and its Authorized Generic)

EPIPEN (epinephrine injection, USP) 0.3 mg and EPIPEN JR (epinephrine injection, USP) 0.15 mg Auto-Injectors are intended for immediate administration as emergency supportive therapy only and are not intended as a substitute for immediate medical or hospital care. In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care. More than two sequential doses of epinephrine should only be administered under direct medical supervision.

Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection.

Important Safety Information (the following information applies to both Epipen and its Authorized Generic)

EPIPEN (epinephrine injection, USP) 0.3 mg and EPIPEN JR (epinephrine injection, USP) 0.15 mg Auto-Injectors are intended for immediate administration as emergency supportive therapy only and are not intended as a substitute for immediate medical or hospital care. In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care. More than two sequential doses of epinephrine should only be administered under direct medical supervision.

EPIPEN and EPIPEN JR should only be injected into the anterolateral aspect of the thigh. Do not inject intravenously, into buttock, or into digits, hands, or feet. Instruct caregivers to hold the leg of young children firmly in place and limit movement prior to and during injection to minimize risk of injection-related injury.

Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop symptoms of infection such as persistent redness, warmth, swelling, or tenderness at the injection site.

Epinephrine should be used with caution in patients with heart disease, and in patients who are on drugs that may sensitize the heart to arrhythmias, because it may precipitate or aggravate angina pectoris and produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics.

Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Common adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties.

Indications (the following information applies to both EPIPEN and its Authorized Generic)

EPIPEN and EPIPEN JR Auto-Injectors are indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. EPIPEN and EPIPEN JR Auto-Injectors are intended for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions.

Click here for Full Prescribing Information for EPIPEN.
Click here for Full Prescribing Information for the Authorized Generic for EPIPEN.

  • About Anaphylaxis
  • About EPIPEN  and Its Authorized Generic
  • For Healthcare Partners
  • Access to EPIPEN  and Its Authorized Generic

    • References

    1. Wood RA, Camargo CA Jr, Lieberman P, et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133(2):461-467.
    2. Simons FE. Anaphylaxis. J Allergy Clin Immunol. 2010;125(2)(suppl 2):S161-S181.
    3. Boyce JA, Assa'd A, Burks AW, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol. 2010;126(6)(suppl):S1-S58.
    4. EPIPEN (epinephrine) injection. Prescribing & Patient Information. 2023. Mylan Specialty L.P. Morgantown WV.
    5. EPINEPHRINE (epinephrine) injection. Prescribing & Patient Information. 2023. Mylan Specialty L.P. Morgantown.
    6. Data on file: Mylan Specialty L.P., IMS Report (1987-August 2018).
  • About Anaphylaxis
  • About EPIPEN  and Its Authorized Generic
  • For Healthcare Partners
  • Access to EPIPEN  and Its Authorized Generic
    • Logo

    You are now leaving Viatris Inc.'s website.

    The website you are about to access is not owned or controlled by Viatris Inc.

    VIATRIS INC. ASSUMES NO RESPONSIBILITY FOR, AND MAKES NO REPRESENTATION AS TO THE ACCURACY OF, ANY CONTENT CONTAINED ON THE WEBSITE YOU ARE ABOUT TO ACCESS.

    OK
    Cancel
    main-logo

    This site is intended for US healthcare professionals.

    If you are a patient, please check out our site for patients.

    Go to Patient Site
    Proceed to Healthcare Professional Site
    Logo

    Prescribing Information

    Please select from the following:

    Continue
    Cancel
    Logo

    Patient Information

    Please select from the following:

    Continue
    Cancel